D-Wave Quantum: A 94.31% Lung-Cancer Simulation, a Faster Solver and an LG CNS Handshake Converge on Today's Q3 Report
Published on 11/10/2026 at 09:51 | Editorial boerse-global.de
D-Wave Quantum has spent the past fortnight stacking up announcements — a faster solver, a training curriculum, a non-binding LG CNS accord and a preliminary lung-cancer study. This morning, before the opening bell, the quantum-computing group must show whether any of it is translating into revenue. Its third-quarter report, covering the period ended September 30, 2026, lands alongside a webcast scheduled for 8:00 a.m. ET, and B. Riley Securities has kept its buy rating on the stock heading into the release.
The shares were up 2.0% at EUR 10.41 on the day of publication, adding to the prior session's 6.6% advance. That earlier rally owed less to D-Wave's own news than to the wider quantum sector: media reports credited strong quarterly figures and a raised revenue outlook from IonQ with lifting sentiment across the group. Sector optimism, however, is a borrowed tailwind. What investors weigh today is D-Wave's own commercial execution.
Tools, training and a Korean partnership
The company's recent disclosures give the bulls something to work with. Roughly a week ago it unveiled improvements to its hybrid Stride solver; by its own account, the new version produced better solutions in 15 seconds than its predecessor managed in 120 seconds during comparative tests. A three-course learning path on applied quantum optimization followed — a signal that D-Wave wants easier onboarding to feed usage of its optimization products.
Should investors sell immediately? Or is it worth buying D-Wave Quantum?
Two weeks back came the LG CNS agreement. The non-binding memorandum of understanding sets out joint work on quantum-optimization applications and shared go-to-market opportunities across South Korea and international markets, with both deployment of applications and market-access avenues named as objectives. The caveat is built into the structure: an MoU is worth only as much as the implementation that follows, and investors will want to see concrete applications and commercial relationships emerge from it.
Customer projects offer a third data point. Shionogi, a D-Wave client, took first place in the quality-of-life category of the NEDO Challenge on October 28 for its quantum-computing work in drug discovery, with the prize money earmarked to fund further research. The continuation of such collaborations matters to the investment case, provided the research matures into durable, usable methods.
A preliminary result, flagged as such
Then there is the medical research. On November 2, scientists at Florida Atlantic University published a study on predicting lung cancer from limited data using D-Wave's annealing hardware, exploring what quantum computing can do when the dataset is thin. The accuracy figures were striking — 94.31% in simulation and 91.90% on quantum hardware — but the company itself explicitly labeled the findings preliminary and pointed to an expanded dataset as the next step. Whether further research strengthens transferability is the question that counts; additional validation and practical deployment will take time, and shareholders should price in a longer development road.
What the numbers must settle
That leaves today's report as the arbiter. Revenue is the metric to watch, since it is the clearest gauge of whether improved tooling and training are converting into economic use of D-Wave's offerings. If the figures and management's commentary on demand back up the commercial narrative, the recent recovery gains a company-specific foundation and the positive scenario acquires substance. If operational progress lags the market's commercialization hopes, a more cautious reading of the sector tailwind is in order. The yardstick, either way, is the link between more capable products and a business that can stand on its own.
Ad
D-Wave Quantum Stock: New Analysis - 10 November
Fresh D-Wave Quantum information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
